Document Detail


Pamidronic acid and Paget's disease: new indication. Short-course treatment.
MedLine Citation:
PMID:  11503825     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
(1) Pamidronic acid, a diphosphonate, is now approved for intravenous treatment of Paget's disease in France. Treatment is given over two to three days, in hospital, and can be repeated six months later. (2) The clinical file contains only non comparative trial data suggesting that a total dose of 180-210 mg has a clinical benefit in most patients and tends to normalise biochemical criteria thought to reflect disease progression. (3) Because no comparative trials have been done, there is no way of knowing whether a short course of intravenous pamidronic acid is any more or less effective that long-term oral etidronic acid or tiludronic acid therapy. However, in the non comparative trials a number of patients who had become resistant to oral diphosphonate therapy had a clinical and/or biochemical response to intravenous pamidronic acid. (4) While intravenous pamidronic acid is well tolerated overall, the precise incidence of its adverse effects on bone (transient increase in pain, osteomalacia) and the eyes (uveitis) is not known.
Authors:
-
Related Documents :
7055985 - Identification of calcium palmitate in gallstones by infra-red spectroscopy.
2551765 - Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind...
19017045 - Topical 5-aminolevulinic acid photodynamic therapy for recalcitrant facial flat wart in...
11136285 - Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol...
12949395 - Influence of vegetable protein sources on trace element and mineral bioavailability.
23400355 - Cervical digital photography for screening of uterine cervix cancer and its precursor l...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Prescrire international     Volume:  8     ISSN:  1167-7422     ISO Abbreviation:  Prescrire Int     Publication Date:  1999 Aug 
Date Detail:
Created Date:  2001-03-29     Completed Date:  2001-03-29     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9439295     Medline TA:  Prescrire Int     Country:  FRANCE    
Other Details:
Languages:  eng     Pagination:  104-6     Citation Subset:  T    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Diphosphonates* / administration & dosage,  adverse effects,  therapeutic use
Drug Approval
Eye Diseases / chemically induced
France
Humans
Infusions, Intravenous
Osteitis Deformans* / drug therapy
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Diphosphonates

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Our correspondence with the World Health Organization about the hypertension guidelines.
Next Document:  Codeine for child pain: new preparation. Helpful in some cases.